Drug Approval | June 13, 2026
UK approves Wegovy pill in major shift in obesity treatment options
Approval is based on results from the phase 3 OASIS 4 clinical trial
Approval is based on results from the phase 3 OASIS 4 clinical trial
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The move signals a major expansion in access to next-generation weight-loss therapies
Nearly one in five women worldwide are now living with obesity
The standout story remains Wegovy, particularly its new oral formulation
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
